Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a neutral rating to an overweight rating in a research note issued to investors on Monday, Marketbeat.com reports.

A number of other research analysts also recently weighed in on BAYRY. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Wall Street Zen upgraded Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 2.0%

Bayer Aktiengesellschaft stock opened at $10.69 on Monday. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $10.70. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The firm has a market capitalization of $42.01 billion, a price-to-earnings ratio of -118.76, a P/E/G ratio of 5.31 and a beta of 0.69. The company has a 50 day moving average price of $8.34 and a 200 day moving average price of $8.05.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.